00:45

The promise of SEMA4D as a target in neurodegenerative diseases

07:56

Impact of race and ethnicity on amyloid-PET results

01:54

Fluid biomarkers of tau pathology

02:30

The role of EEG as a biomarker in Alzheimer's disease trials

02:16

Reducing caregiver burden with a digital care coordination platform

02:50

The future of Alzheimer’s disease diagnosis: blood biomarkers and amyloid-PET

01:27

Impact of disease modifying therapy introduction on symptomatic treatment use in Alzheimer's disease

02:24

Considering the clinical significance of current anti-amyloid therapies

06:42

Current pharmacological approaches in Alzheimer's disease

07:43

Measuring treatment effect in Alzheimer’s disease clinical trials: the ‘time saved’ approach

03:16

Amyloid-PET positivity cut-offs: insights from INTERCEPT-AD

02:25

Plasma biomarkers for population-based Alzheimer’s disease screening

04:23

Speech biomarkers for cognitive decline detection

07:25

ACU193 in Alzheimer's disease: insights from the INTERCEPT AD study

02:03

SIGNAL-AD study of pepinemab in Alzheimer’s disease

07:41

SEMA4D as a therapeutic target: insights from SIGNAL-HD and implications for Alzheimer's disease

04:02

Unraveling the oligomer hypothesis in Alzheimer’s disease

02:31

Implementation of personalized prevention strategies for dementia

03:32

Current evidence for personalized risk reduction in dementia

03:42

Imaging markers in vascular cognitive impairment: the present

02:13

Amyloid reduction as a surrogate endpoint in Alzheimer’s disease trials: insights from DIAN-TU

03:19

Objective monitoring of activities of daily living: IADLSys Smart-Home approach

03:32

Plasma p-tau217: a cost-effective and practical surrogate biomarker for clinical trials

03:10

Months saved with treatment as a measure of clinical meaningfulness in AD clinical trials

02:20

Trial of hearing rehabilitation to slow cognitive decline in patients with MCI

02:49

Testing anti-amyloid therapies in preclinical Alzheimer's disease

01:11

Testing disease modificaition with open label extension studies

02:24

Importance of addressing age-related hearing loss

01:36

Applying industry standards to improve the efficiency of drug development

01:31

Efficient use of open label extension data

01:43

A benchmark for future disease-modifying therapies in Alzheimer’s disease

02:30

Challenges in assessing disease modification in Alzheimer’s disease clinical trials

01:12

Optimism for NK cell therapy as a future Alzheimer’s disease treatment

02:17

Financial hurdles facing robotic assistive technology in dementia care

01:12

The link between hearing loss and dementia: increased cognitive load

01:45

Understanding compensatory factors in healthy individuals with Alzheimer’s pathology

02:41

Hearing loss and dementia: peripheral vs central aspects

01:13

Current research into NK cell therapy and the potential for use in other conditions

01:51

Role of platelet aggregation in dementia risk

01:20

Blood-based brain-derived tau in Alzheimer’s disease

02:00

Molecular processes driving psychosis in Alzheimer’s disease

02:38

Treating patients with hearing loss and cognitive impairment

04:17

AI with advanced retinal imaging techniques to detect neurodegenerative disease risk markers

04:34

Gut microbiome composition and cognitive function in middle-aged adults

01:16

Measuring cognitive impairment in early Alzheimer’s disease

02:28

Immune activation states in Alzheimer’s disease mouse models

01:24

Natural killer cell integrity within Alzheimer's disease

01:57

Biomarkers in DLB trials

01:16

Multi-PET tracers reveal the complex nature of 4R tauopathies

02:07

Use of machine learning to identify signs of cognitive decline

01:19

Late-life major depression impacts plasma Aβ dynamics

01:27

Prioritizing diversity in Alzheimer’s disease biomarker studies

01:05

Using neuropsychiatric symptoms as clinical markers for dementia diagnosis

01:44

PET imaging of reactive astrogliosis in Alzheimer’s disease

01:08

APOE-induced lipid changes and Alzheimer's disease pathogenesis

02:36

Using 7-Tesla MRI to study cerebral impacts of COVID-19 infection

02:06

Retinal protein aggregates as biomarkers in Alzheimer’s and Parkinson’s disease.

01:05

Brain-body communication in neurodegenerative diseases

01:16

Contextualizing the World-Wide FINGER trials in the real-world

01:47

Exercise as a non-pharmacological therapy for cognitive impairment